Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

advanced breast cancer

- PMLiVE

China’s homecoming heroes fuel a biotech boom with rapid CAR-T advances

China secures a place at the forefront of innovative medicine

AstraZeneca AZ

AZ’s Imfinzi plus tremelimumab combo misses again

Drug missed endpoint in small cell lung cancer trial

- PMLiVE

EU grants approval for Venclyxto/Gazyvaro combo in CLL

Chemotherapy-free option for previously-untreated patients

- PMLiVE

Potential universal flu vaccine shows efficacy in clinical trial

Candidate will now move forward into late-stage testing

AstraZeneca AZ

AZ’s comeback drug cediranib stumbles in phase 3 trial

Failed to improve on platinum-based chemotherapy

AstraZeneca AZ

AstraZeneca’s Imfinzi fails first-line bladder cancer test

Unable to improve overall survival in advanced metastatic bladder cancer

AstraZeneca AZ

AZ revenues rise, but it says coronavirus could hit 2020

Product sales up 12% to $23.57bn for the full-year

- PMLiVE

AZ, Daiichi Sankyo’s Enhertu set fair for filing in gastric cancer

Improved overall survival when compared to chemotherapy

- PMLiVE

AZ says Brilinta hits the mark in new stroke trial

Drug met primary endpoint in phase 3 THALES trial

AstraZeneca AZ

AZ’s Imfinzi scores orphan drug status in liver cancer

Company is looking to gain approval in the first-line advanced setting

- PMLiVE

J&J wins another label expansion for Darzalex in Europe

Multiple myeloma treatment indicated for early use

- PMLiVE

AZ, Merck win FDA approval for Lynparza in pancreatic cancer

New treatment option for subset of patients with BRCA-mutations

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links